Aquestive Therapeutics, Inc. (AQST) Operating income 2017–2025
Aquestive Therapeutics, Inc. (AQST) annual operating income history from SEC filings — each fiscal year as reported.
-$71.1MFY2025 · since FY2017: -$113,000 → -$71.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$71.1M | -130.9% |
| FY2024 | -$30.8M | -103.8% |
| FY2023 | -$15.1M | +64.1% |
| FY2022 | -$42.1M | -21.3% |
| FY2021 | -$34.7M | +19.1% |
| FY2020 | -$42.9M | +18.6% |
| FY2019 | -$52.7M | -7.6% |
| FY2018 | -$48.9M | -43204.4% |
| FY2017 | -$113,000 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AQST financial trends
AQST RevenueAQST Net incomeAQST Net marginAQST Gross profitAQST Gross marginAQST Operating marginAQST Operating cash flowAQST Free cash flowAQST Capital expendituresAQST Return on equityAQST Stock buybacksAQST Dividends paidAQST Total assetsAQST Total liabilitiesAQST Shareholders’ equityAQST overview →